Related Experiment Video
Updated: Feb 25, 2026
07:01
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
10.9K
Prognostic impact of CD133 expression in Endometrial Cancer Patients
G Mancebo1,2, J M Sole-Sedeno3, O Pino4,5
1Obstetrics and Gynaecology Department of Hospital Universitari del Mar, Passeig Marítim, 25-29, 08003, Barcelona, Catalonia, Spain. gmancebo@hospitaldelmar.cat.
Scientific Reports
|August 11, 2017
Summary
CD133 expression in endometrioid endometrial carcinoma (EEC) is linked to a better prognosis. CD133-positive tumors show improved progression-free survival and overall survival, indicating a favorable outcome for EEC patients.
Area of Science:
- Gynecology
- Oncology
- Cancer Biomarkers
Background:
- Endometrioid endometrial carcinoma (EEC) is a common gynecological malignancy.
- CD133 is a cell surface marker investigated for its role in various cancers.
- The prognostic significance of CD133 in EEC requires further elucidation.
Purpose of the Study:
- To evaluate the impact of CD133 expression on the clinical outcomes of EEC.
- To determine the correlation between CD133 status and clinicopathological features in EEC.
- To assess CD133 as a potential prognostic biomarker for EEC.
Main Methods:
- Retrospective analysis of 116 surgically treated FIGO I-III EEC cases.
- Tissue microarrays were used to assess CD133 expression.
- Tumors with ≥10% CD133-expressing cells were classified as CD133-positive (CD133+).
- Progression-free survival (PFS) and overall survival (OS) were analyzed based on CD133 expression.
Main Results:
- 85.2% of EEC cases exhibited CD133-expressing cells; 61% were CD133+.
- CD133+ tumors were associated with significantly longer mean OS (161 months) and PFS (159 months) compared to CD133- tumors.
- CD133+ status correlated with a lower likelihood of vascular invasion (p=0.010) and a higher likelihood of well-differentiated tumors (p=0.034).
- CD133+ tumors predicted favorable OS and PFS with a Hazard Ratio of 4.731 (p=0.022).
Conclusions:
- CD133 expression is a significant positive prognostic factor in endometrioid endometrial carcinoma.
- CD133+ tumor status correlates with improved survival outcomes and favorable clinicopathological features in EEC.
- These findings suggest CD133 may serve as a valuable biomarker for predicting EEC prognosis, consistent with observations in other tumor types.
